GENE ONLINE|News &
Opinion
Blog

2022-03-14| R&D

Cancer Cells Rewire the Genetic Code to Overcome Amino Acid Depletion

by Sahana Shankar
Share To

Profiling the working of a tumor cell in comparison to a healthy cell provides a mechanistic view of their response to the host immune system. In a new study from the Netherlands Cancer Institute, Amsterdam and Rotterdam University, researchers demonstrate that tumor cells can swap amino acids during protein translation if there is a shortage.

The central dogma of molecular biology is that the genetic code is faithfully transcribed and translated into a functional protein because cells have unique ribosomal components called t-RNA which read the codons on the mRNA to incorporate the corresponding amino acids to build a protein chain. When the immune system detects a tumor cell in the vicinity, the T cells mount an attack by releasing interferon-γ. Authors of this report show that interferon-γ causes a shortage of one particular amino acid, tryptophan in tumor cells which evade the problem by replacing it with another similar-structured amino acid, phenylalanine, suggesting that tumor cells have a codon reassignment strategy to overcome amino acid depletion. 

 

Proteome-wide and Cancer-specific 

 

The study, led by Dr. Reuven Agami, head of the Division of Oncogenomics at the Netherlands Cancer Institute, identified that WARS1, tryptophanyl t-RNA synthetase could add phenylalanine(F) to the peptide chain in the event of tryptophan (W) unavailability. This phenomenon is unique to cancerous cells since no W>F substitution was observed in normal tissues. Analysis of cancer proteomes showed an enrichment of W>F clusters. 

This reassignment could provide both advantages and disadvantages to the tumor cells. While the substitution allows for protein synthesis to proceed despite amino acid shortages, it could result in proteins with altered 3D conformation, active sites and substrate specificity for enzymatic activity. It also triggers an immune response by antigen-presentation of modified proteins. This can be exploited to dial up the immune response in the tumor microenvironment. 

Mutations cause fixed changes in protein structure and function. However, amino acid substitutions are induced due to the cell’s adjustment to cellular restrictions during mRNA translation which cause broad range changes to the proteome. 

The authors provide yet another example of conditional reassignment in the genetic code which has been previously observed in mitochondrial proteins, microbes in stressful conditions, and mammals responding to viral infections. The substitution occurs across a range of tumors which could help develop generic anti-tumor therapeutics. Further work on disease-specific substitutions could unravel other less understood rules of the genetic code. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
The Fight Against Hard-to-Treat Cancers : Bold Bets on a Multifaceted Approach
2025-05-19
The Buffett Paradox: Cola, Happiness, and a Biotech Longevity Enigma
2025-05-11
AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances
2025-04-28
LATEST
Chemical Method Developed to Reprogram Human T Cells into Pluripotent Stem Cells
2026-01-16
Study Finds Acute Pancreatitis Worsens Outcomes for Pediatric Stem Cell Transplant Patients
2026-01-16
Study Explores Patient Perspectives on Frailty Screening Implementation in Emergency Departments
2026-01-16
Researchers Identify SMPDL3B as Potential Biomarker and Therapeutic Target for Myalgic Encephalomyelitis
2026-01-16
Study Explores Transcriptomic Changes in Cryopreserved Human Ovarian Tissue Using 3D Culture Techniques
2026-01-16
Nanomedicine Explored as a Tool to Address Healthcare Disparities in Head and Neck Cancer Treatment in Brazil
2026-01-16
Hybrid Ambient Documentation Combines Real-Time Data Streaming with Traditional Clinical Records in Healthcare
2026-01-16
EVENT
2026-02-09
World Health Expo Dubai
Dubai Exhibition Centre, Dubai
2026-02-17
BIO Asia 2026 (Life Science Partnerships)
Hyderabad, India
2026-02-24
Rare Disease Week on Capitol Hill (Policy and Advocacy)
Capitol Hill, Washington, D.C.
2026-03-09
HIMSS26 (Digital Health & Hospital IT)
Las Vegas, Nevada
Scroll to Top